Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures as an antibody-based diagnostic platform in the United States and the rest of the world.
The Immunosignature Technology was invented and originally developed by Stephen Albert Johnston, now CEO of Calviri, and his colleagues at ASU. The platform uses hundreds of thousands of chemically diverse peptides to provide an unbiased profile of an individual’s antibody repertoire. It has been applied to both infectious and chronic diseases in published reports. Initially intended as simply a diagnostic tool to detect disease onset, additional work has shown its potential for measuring disease severity and response to therapies.
Cheaper refrigerators? Stronger hip implants? A better understanding of human disease? All of these could be possible and more, someday, thanks to an ambitious new project underway at the National Institute of Standards and Technology (NIST).
NIST researchers are in the early stages of a massive undertaking to design and build a fleet of tiny ultra-sensitive thermometers. If they succeed, their system will be the first to make real-time measurements of temperature on the microscopic scale in an opaque 3D volume — which could include medical implants, refrigerators, and even the human body.
The project is called Thermal Magnetic Imaging and Control (Thermal MagIC), and the researchers say it could revolutionize temperature measurements in many fields: biology, medicine, chemical synthesis, refrigeration, the automotive industry, plastic production — “pretty much anywhere temperature plays a critical role,” said NIST physicist Cindi Dennis. “And that’s everywhere.”
In a collaborative effort between scientists and personnel on military bases in 31 states in the continental U.S. and Puerto Rico, researchers surveyed for an infection caused by an emerging fungal pathogen that afflicts snakes. The effort found infected snakes on military bases in 19 states and Puerto Rico, demonstrating that the fungus is more widely distributed than was previously known. The team reports the findings in the journal PLOS ONE.
“Ophidiomycosis — formerly known as ‘snake fungal disease’ — is an emerging infectious disease caused by the fungus Ophidiomyces ophidiicola,” said Dr. Matt Allender, a professor in the veterinary diagnostic laboratory at the University of Illinois Urbana-Champaign who led the new study. “It has been documented in over 15 genera of wild and captive snakes. Infection with the pathogen causes a wide range of clinical signs in snakes, from difficulty shedding skin, to crusts and ulcers on the
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences have used a combination of genome-wide association analysis — or GWAS — and a trans-ancestry comparison of different GWAS studies, to come up with a more accurate predictor of coronary artery disease based on genetic factors.
It is known that coronary artery disease — the world’s leading cause of death — is highly heritable, and in some cases, most notably the PCSK9 gene, the knowledge of genetic associations has contributed to the development of therapies. Genetic Risk Scores based on genetic information can accurately predict the onset of disease in individuals. However, studies so far have focused primarily on European populations, and it is not clear whether the results apply to other ancestry populations.
In the present study, published in Nature Genetics, the team performed two important tasks. First, they looked at the genetics of
Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers.
Led by Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumor board was established to advise treating physicians on course of care using an individual patient’s molecular tumor makeup to design precision medicine strategies.
“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that
On the campaign trail, Trump’s sons Donald Jr. and Eric have spoken to packed audiences in indoor venues. And the Trump campaign violated state regulations limiting the size of gatherings in Nevada, earning a public rebuke from the governor after the president addressed thousands at an indoor event there last month.
They all took their cues from Trump himself, who has rarely worn masks, sometimes mocked those who did and disputed the advice from his own government’s experts.
While the nation suffered through an unprecedented and fear-filled lockdown, there was a bubble at the top, where Trump’s actions seemed to flout the laws of disease, and to embolden — or coerce —those around him to try it, too.
Asked by The Washington Post’s Bob Woodward earlier this year if he was afraid of catching the virus, he said he wasn’t. “I don’t know why I’m not,” he said, according
A new study of approximately 80,000 patients shows that people with Parkinson’s disease (PD) have a 30% higher risk of dying from COVID-19 than people without the neurodegenerative condition.
The new analysis conducted by researchers with University of Iowa Health Care based on patient data in the TriNetX COVID-19 research network suggests that Parkinson’s disease is an independent risk factor for dying from COVID-19.
The UI research team led by neurologists Qiang Zhang, MD, and Nandakumar Narayanan, MD, PhD, identified the COVID-19 patient cohort as of July 15 and analyzed the mortality data eight weeks later. They found that 5.5% (4,290 out of 78,355) of COVID-19 patients without PD died compared to 21.3% (148 of 694) COVID-19 patients who also had PD.
However, the patients with PD were generally older, more likely to be male, and less likely to be African American than the patients without PD. All of these
Farm Health Guardian™, a new real-time disease mitigation technology platform, is now available for pork and poultry producers and integrators throughout North America, Europe and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005463/en/
The Farm Health Guardian platform offers real-time disease mitigation for poultry and pork producers. (Graphic: Business Wire)
Brought to market by Be Seen Be Safe Ltd., the innovative system accurately and quickly tracks and shuts down disease spread within minutes of the first report of disease symptoms.
Jonathan Sawatzky VP, Maple Leaf Agri-Farms Manufacturing says, “Farm Health Guardian has provided our business with a platform to manage our farm movements and provide excellent and timely trace back abilities and communication in our Farm system.”
“The Farm Health Guardian system is the first complete disease spread mitigation platform of its kind,” says Tim Nelson, Founder and President, Be Seen Be Safe. “Quick
New findings suggest that late-onset Alzheimer’s Disease is driven by epigenetic changes — how and when certain genes are turned on and off — in the brain. Results were published today in Nature Genetics.
Research led by Raffaella Nativio, PhD, a former research associate of Epigenetics, Shelley Berger, PhD, a professor of Genetics, Biology and Cell and Developmental Biology and Director of the Epigenetics Institute, and Nancy Bonini, PhD, a professor of Biology and Cell and Developmental Biology, all in the Perelman School of Medicine at the University of Pennsylvania, used post-mortem brain tissue to compare healthy younger and older brain cells to those with Alzheimer’s Disease. The team found evidence that epigenetic regulators disable protective pathways and enable pro-disease pathways in those with the disease.
“The last five years have seen great efforts to develop therapeutics to treat Alzheimer’s disease, but sadly, they have failed in the clinic
Technavio has been monitoring the dengue vaccine market and it is poised to grow by $ 630.65 million during 2020-2024, progressing at a CAGR of over 26% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200925005218/en/
Technavio has announced its latest market research report titled Global Dengue Vaccine Market 2020-2024 (Graphic: Business Wire)
Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. We offer $1000 worth of FREE customization